Capsid News and Research

RSS

Assembly Pharmaceuticals, BioCrossroads develop novel drugs that have potential to treat chronic HBV infection

Assembly Pharmaceuticals and BioCrossroads today announced that the BioCrossroads Indiana Seed Fund II has made an investment in Assembly Pharmaceuticals. Assembly is developing novel drugs for the treatment and potential cure of chronic hepatitis B virus (HBV) infection.

10 Apr 2014

Researchers provide new insights into how common cold virus infects

On average, each of us catches a cold two to three times a year. However, how the common cold virus actually infects us is only partly understood. Researchers from the Max F. Perutz Laboratories of the Medical University of Vienna and the University of Vienna, in collaboration with two Spanish groups, have now provided new insights into this process.

30 Dec 2013

Scientists explore mechanisms of viruses' shells

Viruses are like small vessels containing an active component, the genetic material, that can infect a host cell. The vessel, called capsid or vector, is basically a shell that changes its shape when it penetrates a cell to infect it, and may even break into pieces.

12 Dec 2013

Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression

Successful gene therapy is based on the effective delivery and maintained expression of healthy copies of a gene into tissues of individuals with a disease-associated genetic mutation.

16 Nov 2013

Rice researchers frame rules to design viral capsid proteins for gene therapy

Rice University researchers are making strides toward a set of rules to custom-design Lego-like viral capsid proteins for gene therapy.

13 Aug 2013

Discovery of pressure-driven infection mechanism opens door to new treatments for viral infections

The virus that causes those painful lip blisters known as cold sores has an internal pressure eight times higher than a car tire, and uses it to literally blast its infectious DNA into human cells, scientists are reporting in a new study.

25 Jul 2013

CHOP-led research increases numbers of patients who could be treated with gene therapy

Gene therapy researchers have produced a bioengineered decoy that fools the immune system and prevents it from mistakenly defeating the benefits delivered by a corrective gene.

18 Jul 2013

Researchers determine precise chemical structure of HIV capsid

Researchers have determined the precise chemical structure of the HIV capsid, a protein shell that protects the virus's genetic material and is a key to its ability to infect and debilitate the human body's defense mechanism.

1 Jun 2013

Scientists move closer to understanding HIV-1 infection

Scientists have long been unable to fully explain how infections attack the body, but now a team of researchers, including one from the University of Central Florida, has taken a step closer to understanding how the process works in HIV-1. The results mean that one day that knowledge may prevent infection.

31 May 2013

Newly characterized adenoviruses can cause severe human infections

The ongoing dance between a virus and its host distinctly shapes how the virus evolves. While human adenoviruses typically cause mild infections, recent reports have described newly characterized adenoviruses that can cause severe, sometime fatal, human infections.

12 Apr 2013

Researchers develop new approach for HIV vaccine development

Decades of research and three large-scale clinical trials have so far failed to yield an effective HIV vaccine, in large part because the virus evolves so rapidly that it can evade any vaccine-induced immune response.

22 Mar 2013

Findings provide structural basis for development of drugs to fight enterovirus 71 infection

New research findings may help scientists design drugs to treat a virus infection that causes potentially fatal brain swelling and paralysis in children.

22 Mar 2013

New model of how the capsid of viruses assembles

A new model of the how the protein coat (capsid) of viruses assembles, published in BioMed Central's open access journal BMC Biophysics, shows that the construction of intermediate structures prior to final capsid production (hierarchical assembly) can be more efficient than constructing the capsid protein by protein (direct assembly).

17 Dec 2012

Novira secures $23M in Series A financing to support antiviral development for HBV, HIV

Novira Therapeutics Inc. today announced it has secured $23 million in Series A financing to support the development of its capsid-targeting antivirals for the treatment of chronic hepatitis B (HBV) and HIV infections.

24 Aug 2012

Bristol-Myers Squibb, Prosetta partner to discover and develop new antiviral drugs

Prosetta Antiviral Inc today announced the execution of a strategic alliance with Bristol-Myers Squibb Company to further discover and develop select drug candidates representing new, novel classes of antiviral drugs.

31 Jul 2012

EBV can infect and may also contribute to lymphomas in man's best friend

More than 90 percent of humans have antibodies to the Epstein Barr virus. Best known for causing mononucleosis, or "the kissing disease," the virus has also been implicated in more serious conditions, including Hodgkin's, non-Hodgkin's and Burkitt's lymphomas. Yet little is known about exactly how EBV triggers these diseases.

13 Mar 2012

Scripps Florida receives NIH grant to create novel HIV inhibitors

A Scripps Florida team has been awarded nearly $1.5 million by the National Institutes of Health to identify and develop novel potent inhibitors of the human immunodeficiency virus (HIV), the cause of AIDS.

27 Feb 2012

Tetragenetics reports results from G-SOME H5N1 vaccine preclinical study

Tetragenetics Inc., a biotechnology company focused on the development of recombinant vaccines, today reported preclinical study results showing that an investigational nanoparticle-based influenza vaccine protects against a highly pathogenic H5N1 avian influenza strain.

6 Jan 2012

IP-K and Sanofi form new HBV research collaboration

One of the most common and serious infectious diseases, Hepatitis B, is to be targeted in a new collaborative venture between the internationally-renowned translational research institute, Institut Pasteur Korea (IP-K), and the Korean arm of the leading global healthcare company, Sanofi-Aventis Korea. The goal is to develop and validate a high throughput assay to screen IP-K's chemical libraries for novel compounds that can be developed as new drugs.

3 Nov 2011

Scientists define structure of astrovirus that causes juvenile diarrhea

Rice University scientists have defined the structure -- down to the atomic level -- of a virus that causes juvenile diarrhea. The research may help direct efforts to develop medications that block the virus before it becomes infectious.

19 Jul 2011